参考文献/References:
[1]Rouprêt M,Seisen T,Birtle AJ,et al.European Association of Urology guidelines on upper urinary tract urothelial carcinoma:2023 update.Eur Urol,2023,84(1):49-64.
[2]Seisen T,Peyronnet B,DominguezEscrig JL,et al.Oncologic outcomes of kidneysparing surgery versus radical nephroureterectomy for upper tract urothelial carcinoma:a systematic review by the EAU nonmuscle invasive bladder cancer guidelines panel.Eur Urol,2016,70(6):1052-1068.
[3]Rouprêt M,Babjuk M,Compérat E,et al.European Association of Urology guidelines on upper urinary tract urothelial cell carcinoma:2015 update.Eur Urol,2015,68(5):868-879.
[4]Rouprêt M,Babjuk M,Compérat E,et al.European Association of Urology guidelines on upper urinary tract urothelial carcinoma:2017 update.Eur Urol,2018,73(1):111-122.
[5]Dudinec JV,OrtizMelo DI,Lipkin ME,et al.Advanced chronic kidney disease:a comparison between nephroureterectomy and nephronsparing surgery for upper tract urothelial carcinoma.Urol Oncol,2023,41(6):295.e19-295.e25.
[6]Su X,Fang D,Zhang L,et al.Treatment strategies for upper tract urothelial carcinoma (UTUC) of a solitary kidney:a singleinstitutional analysis of 61 cases.Int Urol Nephrol,2016,48(10):1601-1608.
[7]Zhang A,Shang D,Zhang J,et al.A retrospective review of patients with urothelial cancer in 3,370 recipients after renal transplantation:a singlecenter experience.World J Urol,2015,33(5):713-717.
[8]郝运,王艳波,王艺昧,等.浸润性高级别肾盂癌术前CT误诊为肾癌2例病例报道.重庆医学,2019,48(1):138-139.
[9]Li Y,Ding YU,Chen D,et al.Renal cell carcinoma growing into the renal pelvis and mimicking transitional cell carcinoma:a case report and literature review.Oncol Lett,2015,9(4):1869-1872.
[10]Razavi SA,Sadigh G,Kelly AM,et al.Comparative effectiveness of imaging modalities for the diagnosis of upper and lower urinary tract malignancy:a critically appraised topic.Acad Radiol,2012,19(9):1134-1140.
[11]Yeh HC,Chang CH,Fang JK,et al.The value of preoperative local symptoms in prognosis of upper tract urothelial carcinoma after radical nephroureterectomy:a retrospective,multicenter cohort study.Front Oncol,2022,12:872849.
[12]Ljungberg B,Albiges L,AbuGhanem Y,et al.European Association of Urology guidelines on renal cell carcinoma:the 2022 update.Eur Urol,2022,82(4):399-410.
[13]Birtle A,Johnson M,Chester J,et al.Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial):a phase 3,openlabel,randomised controlled trial.Lancet,2020,395(10232):1268-1277.
[14]Fang D,Zhang Q,Li X,et al.Nomogram predicting renal insufficiency after nephroureterectomy for upper tract urothelial carcinoma in the Chinese population:exclusion of ineligible candidates for adjuvant chemotherapy.Biomed Res Int,2014,2014:529186.
[15]Balar AV,Castellano DE,Grivas P,et al.Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma:results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of followup.Ann Oncol,2023,34(3):289-299.
[16]Sheng X,Chen H,Hu B,et al.Safety,efficacy,and biomarker analysis of toripalimab in patients with previously treated advanced urothelial carcinoma:results from a multicenter phase II trial POLARIS-03.Clin Cancer Res,2022,28(3):489-497.
[17]Chen J,Wang M,Qi X,et al.RC48antibodydrug conjugate in metastatic urothelial carcinoma:a multicenter realworld study in China.Clin Genitourin Cancer,2024,22(3):102093.